CCNE1基因在卵巢高级别浆液性癌中的研究进展

doi:10.12280/gjfckx.20220089

摘要/Abstract

摘要：

细胞周期蛋白E1（Cyclin E1,CCNE1）基因扩增是卵巢高级别浆液性癌（high-grade serous ovarian carcinoma,HGSOC）最常见的拷贝数变异之一,扩增率为20%左右。CCNE1基因扩增不仅参与HGSOC的早期癌前病变,促进恶性肿瘤的发生、发展,还可引起细胞周期紊乱和染色体不稳定,从而增加HGSOC的铂类耐药性和复发率,最终导致患者的化疗效果不佳和预后较差。为改善CCNE1扩增的HGSOC患者的预后和生活质量,在暂时没有CCNE1扩增的HGSOC的靶向治疗药物的情况下,使用细胞周期蛋白依赖性激酶2（cyclin-dependent kinases 2,CDK2）小分子抑制剂或者多腺苷二磷酸核糖聚合酶[poly (ADP-ribose) polymerase,PARP]抑制剂与其他药物联合治疗,一定程度上能有效地抑制肿瘤细胞的增殖活性,促进肿瘤细胞死亡。因此,从CCNE1扩增对HGSOC的早期发病机制的影响和产生铂类耐药的角度上来说,CCNE1基因有望成为HGSOC的潜在治疗靶标和预后评价生物学指标,在改善患者的治疗和预后方面具有重要意义。

关键词: 卵巢肿瘤, 细胞周期蛋白E, 基因扩增, 药物疗法, 预后, 卵巢高级别浆液性癌

Abstract:

CyclinE1(CCNE1) gene amplification is one of the most common copy number variations in high-grade serous ovarian carcinoma (HGSOC), with an amplification rate of about 20%. CCNE1 gene amplification not only participates in the early precancerous lesions of HGSOC and promotes the occurrence and development of malignant tumors, but also causes cell cycle disorder and chromosome instability, thus increasing platinum resistance and recurrence rate of HGSOC, and ultimately leading to poor chemotherapy effect and poor prognosis of patients. In order to improve the prognosis and quality of life of patients with CCNE1-amplified HGSOC, cyclin-dependent kinases 2(CDK2) small molecule inhibitors or poly (ADP-ribose) polymerase (PARP) inhibitors in combination with other drugs are used to treat CCNE1-amplified HGSOC in the absence of targeted drugs for CCNE1-amplified HGSOC. To a certain extent, it can effectively inhibit the proliferation of tumor cells and promote the death of tumor cells. Therefore, CCNE1 gene is expected to become a potential therapeutic target and prognostic biological indicator of HGSOC from the perspective of the influence of CCNE1 amplification on the early pathogenesis of HGSOC and the generation of platinum resistance, which is of great significance to improve the treatment and prognosis of patients.

Key words: Ovarian neoplasms, Cyclin E, Gene amplification, Drug therapy, Prognosis, High-grade serous ovarian carcinoma

刘艳, 卞伟, 肖虹. CCNE1基因在卵巢高级别浆液性癌中的研究进展[J]. 国际妇产科学杂志, 2022, 49(3): 286-290.

LIU Yan, BIAN Wei, XIAO Hong. LIU Yan, BIAN Wei, XIAO Hong^△[J]. Journal of International Obstetrics and Gynecology, 2022, 49(3): 286-290.

参考文献 38

[1]	Kroeger PT Jr, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer[J]. Curr Opin Obstet Gynecol, 2017, 29(1):26-34. doi: 10.1097/GCO.0000000000000340. doi: 10.1097/GCO.0000000000000340
[2]	Gorski JW, Ueland FR, Kolesar JM. CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer[J]. Diagnostics (Basel), 2020, 10(5):279. doi: 10.3390/diagnostics10050279. doi: 10.3390/diagnostics10050279
[3]	Sapoznik S, Aviel-Ronen S, Bahar-Shany K, et al. CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance[J]. Oncotarget, 2017, 8(37):62240-62247. doi: 10.18632/oncotarget.19272. doi: 10.18632/oncotarget.19272 pmid: 28977941
[4]	Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer[J]. Nature, 2015, 521(7553):489-494. doi: 10.1038/nature14410. doi: 10.1038/nature14410
[5]	Li Y, Li L. Bioinformatic screening for candidate biomarkers and their prognostic values in endometrial cancer[J]. BMC Genet, 2020, 21(1):113. doi: 10.1186/s12863-020-00898-4. doi: 10.1186/s12863-020-00898-4
[6]	Schott C, Shah AT, Sweet-Cordero EA. Genomic Complexity of Osteosarcoma and Its Implication for Preclinical and Clinical Targeted Therapies[J]. Adv Exp Med Biol, 2020, 1258:1-19. doi: 10.1007/978-3-030-43085-6_1. doi: 10.1007/978-3-030-43085-6_1
[7]	Zhao ZM, Yost SE, Hutchinson KE, et al. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer[J]. BMC Cancer, 2019, 19(1):96. doi: 10.1186/s12885-019-5290-4. doi: 10.1186/s12885-019-5290-4
[8]	Integrated genomic analyses of ovarian carcinoma[J]. Nature, 2011, 474(7353):609-615. doi: 10.1038/nature10166. doi: 10.1038/nature10166
[9]	Li J, Fadare O, Xiang L, et al. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis[J]. J Hematol Oncol, 2012, 5:8. doi: 10.1186/1756-8722-5-8. doi: 10.1186/1756-8722-5-8
[10]	Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer[J]. J Pathol, 2001, 195(4):451-456. doi: 10.1002/path.1000. doi: 10.1002/path.1000 pmid: 11745677
[11]	Karst AM, Jones PM, Vena N, et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers[J]. Cancer Res, 2014, 74(4):1141-1152. doi: 10.1158/0008-5472.CAN-13-2247. doi: 10.1158/0008-5472.CAN-13-2247
[12]	Mei J, Tian H, Huang HS, et al. Cellular models of development of ovarian high-grade serous carcinoma: A review of cell of origin and mechanisms of carcinogenesis[J]. Cell Prolif, 2021, 54(5):e13029. doi: 10.1111/cpr.13029. doi: 10.1111/cpr.13029
[13]	Kuhn E, Wang TL, Doberstein K, et al. CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma[J]. Mod Pathol, 2016, 29(10):1254-1261. doi: 10.1038/modpathol.2016.101. doi: 10.1038/modpathol.2016.101
[14]	Venuto S, Merla G. E3 Ubiquitin Ligase TRIM Proteins, Cell Cycle and Mitosis[J]. Cells, 2019, 8(5):510. doi: 10.3390/cells8050510. doi: 10.3390/cells8050510
[15]	Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm[J]. Nat Rev Cancer, 2009, 9(3):153-166. doi: 10.1038/nrc2602. doi: 10.1038/nrc2602 pmid: 19238148
[16]	Pang W, Li Y, Guo W, et al. Cyclin E: a potential treatment target to reverse cancer chemoresistance by regulating the cell cycle[J]. Am J Transl Res, 2020, 12(9):5170-5187. pmid: 33042412
[17]	Maloney SM, Hoover CA, Morejon-Lasso LV, et al. Mechanisms of Taxane Resistance[J]. Cancers (Basel), 2020, 12(11):3323. doi: 10.3390/cancers12113323. doi: 10.3390/cancers12113323
[18]	Otsuka I. Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations[J]. Int J Mol Sci, 2021, 22(9):4409. doi: 10.3390/ijms22094409. doi: 10.3390/ijms22094409
[19]	Hanahan D, Weinberg RA. The hallmarks of cancer[J]. Cell, 2000, 100(1):57-70. doi: 10.1016/s0092-8674(00)81683-9. doi: 10.1016/s0092-8674(00)81683-9 pmid: 10647931
[20]	Etemadmoghadam D, George J, Cowin PA, et al. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer[J]. PLoS One, 2010, 5(11):e15498. doi: 10.1371/journal.pone.0015498. doi: 10.1371/journal.pone.0015498
[21]	Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles[J]. Oncogene, 2005, 24(17):2776-2786. doi: 10.1038/sj.onc.1208613. doi: 10.1038/sj.onc.1208613
[22]	Keck JM, Summers MK, Tedesco D, et al. Cyclin E overexpression impairs progression through mitosis by inhibiting APC(Cdh1)[J]. J Cell Biol, 2007, 178(3):371-385. doi: 10.1083/jcb.200703202. doi: 10.1083/jcb.200703202
[23]	Penner-Goeke S, Lichtensztejn Z, Neufeld M, et al. The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples[J]. PLoS Genet, 2017, 13(4):e1006707. doi: 10.1371/journal.pgen.1006707. doi: 10.1371/journal.pgen.1006707
[24]	Vishwakarma R, McManus KJ. Chromosome Instability; Implications in Cancer Development, Progression, and Clinical Outcomes[J]. Cancers (Basel), 2020, 12(4):824. doi: 10.3390/cancers12040824. doi: 10.3390/cancers12040824
[25]	Chan AM, Enwere E, McIntyre JB, et al. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma[J]. J Pathol Clin Res, 2020, 6(4):252-262. doi: 10.1002/cjp2.168. doi: 10.1002/cjp2.168
[26]	Petersen S, Wilson AJ, Hirst J, et al. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes[J]. Gynecol Oncol, 2020, 157(2):405-410. doi: 10.1016/j.ygyno.2020.01.038. doi: 10.1016/j.ygyno.2020.01.038
[27]	Filippova OT, Selenica P, Pareja F, et al. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women[J]. Gynecol Oncol, 2021, 161(2):545-552. doi: 10.1016/j.ygyno.2021.02.028. doi: 10.1016/j.ygyno.2021.02.028 pmid: 33674143
[28]	Yang L, Fang D, Chen H, et al. Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression[J]. Oncotarget, 2015, 6(25):20801-20812. doi: 10.18632/oncotarget.4600. doi: 10.18632/oncotarget.4600 pmid: 26204491
[29]	Nakayama N, Nakayama K, Shamima Y, et al. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer[J]. Cancer, 2010, 116(11):2621-2634. doi: 10.1002/cncr.24987. doi: 10.1002/cncr.24987 pmid: 20336784
[30]	Aziz D, Etemadmoghadam D, Caldon CE, et al. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes[J]. Gynecol Oncol, 2018, 151(2):327-336. doi: 10.1016/j.ygyno.2018.08.039. doi: 10.1016/j.ygyno.2018.08.039
[31]	Au-Yeung G, Lang F, Azar WJ, et al. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition[J]. Clin Cancer Res, 2017, 23(7):1862-1874. doi: 10.1158/1078-0432.CCR-16-0620. doi: 10.1158/1078-0432.CCR-16-0620 pmid: 27663592
[32]	Etemadmoghadam D, Au-Yeung G, Wall M, et al. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer[J]. Clin Cancer Res, 2013, 19(21):5960-5971. doi: 10.1158/1078-0432.CCR-13-1337. doi: 10.1158/1078-0432.CCR-13-1337 pmid: 24004674
[33]	Mittica G, Ghisoni E, Giannone G, et al. PARP Inhibitors in Ovarian Cancer[J]. Recent Pat Anticancer Drug Discov, 2018, 13(4):392-410. doi: 10.2174/1574892813666180305165256. doi: 10.2174/1574892813666180305165256 pmid: 29512470
[34]	Mirza MR, Coleman RL, González-Martín A, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors[J]. Ann Oncol, 2020, 31(9):1148-1159. doi: 10.1016/j.annonc.2020.06.004. doi: S0923-7534(20)39891-4 pmid: 32569725
[35]	Ibrahim EM, Refae AA, Bayer AM, et al. Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis[J]. Future Oncol, 2020, 16(10):585-596. doi: 10.2217/fon-2020-0057. doi: 10.2217/fon-2020-0057
[36]	Onstad M, Coleman RL, Westin SN. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer[J]. Drugs, 2020, 80(15):1525-1535. doi: 10.1007/s40265-020-01382-0. doi: 10.1007/s40265-020-01382-0
[37]	Kim H, Xu H, George E, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models[J]. Nat Commun, 2020, 11(1):3726. doi: 10.1038/s41467-020-17127-2. doi: 10.1038/s41467-020-17127-2
[38]	Gupta VG, Hirst J, Petersen S, et al. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer[J]. Gynecol Oncol, 2021, 162(1):163-172. doi: 10.1016/j.ygyno.2021.04.015. doi: 10.1016/j.ygyno.2021.04.015